Science:利用空间转录组学技术可视化观察组织中的基因表达

2016-07-04 佚名 生物谷 Bioon.co

在一项新的研究中,来自瑞典卡罗琳斯卡研究所和皇家理工学院等机构的研究人员开发出一种新的被称作空间转录组学(spatial transcriptomics)的高分辨率方法研究一种组织中哪些基因是有活性的。这种方法能够被用于所有类型的组织中,而且在临床前研究和癌症诊断中是有价值的。相关研究结果发表在2016年7月1日那期Science期刊上,论文标题为“Visualization and ana

在一项新的研究中,来自瑞典卡罗琳斯卡研究所和皇家理工学院等机构的研究人员开发出一种新的被称作空间转录组学(spatial transcriptomics)的高分辨率方法研究一种组织中哪些基因是有活性的。这种方法能够被用于所有类型的组织中,而且在临床前研究和癌症诊断中是有价值的。相关研究结果发表在2016年7月1日那期Science期刊上,论文标题为“Visualization and analysis of gene expression in tissue sections by spatial transcriptomics”。

疾病改变组织中RNA分子和蛋白表达。为了获得关于疾病的更多知识和优化诊断方法,对组织样品进行显微研究经常在实验室和医院中开展,但是迄今为止,科学家们只能够同时确定少量RNA分子的位置。

在这项新的研究中,来自瑞典卡罗琳斯卡研究所的Jonas Frisén教授团队与来自瑞典皇家理工学院的Joakim Lundeberg教授团队合作开发出一种新的方法,能够分析所有RNA分子的数量,并且利用显微镜提供它们的空间信息。

Frisén教授说,“通过将组织切片放在载玻片上,在其上面,我们将DNA链与内置的地址标签放在一起,这样我们就能够对活性基因产生的RNA分子进行标记。当我们分析组织样品中的RNA分子存在时,这些地址标签指示着这些RNA分子存在于组织切片中哪些地方,以及我们能够获得在哪些地方不同的基因是有活性的高分辨率信息。”

这些结果也在更加精确的诊断中是有价值的。当前的诊断方法是获取一种组织样品,将它磨碎,分析细胞混合物,但是其风险在于一些癌细胞被来自样品中所有的其他细胞的信号稀释掉,因而被忽略掉。

他继续说道,“利用我们的方法,我们能够获取肿瘤信号,而且不会被稀释掉。鉴于组织样品中的不同部分都有它们的特异性地址标签,我们能够鉴定少量的肿瘤细胞。”研究人员利用小鼠脑瘤和人乳腺癌样品证实了这一点。

这种方法能够用于所有类型的组织和疾病中。它也能够提供关于癌症诊断中的疾病异质性的信息,就像在研究人乳腺癌样品时所证实的那样。

Frisén教授说,“它使得比以往更高分辨率和更精准地研究哪些基因在组织中是有活性的成为可能,而这在基础研究和诊断中是有价值的。”

原始出处:

Patrik L. Ståhl1,2,*, Fredrik Salmén2,*, Sanja Vickovic2,†, Anna Lundmark2,3,†, José Fernández Navarro1,2, Jens Magnusson1, Stefania Giacomello2, Michaela Asp2, Jakub O. Westholm4, Mikael Huss4, Annelie Mollbrink2, Sten Linnarsson5, Simone Codeluppi5,6, Åke Borg7, Fredrik Pontén8, Paul Igor Costea2, Pelin Sahlén2, Jan Mulder9, Olaf Bergmann1, Joakim Lundeberg2,‡, Jonas Frisén.Visualization and analysis of gene expression in tissue sections by spatial transcriptomics.Science.doi:10.1126/science.aaf2403

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1747211, encodeId=5dfe1e47211fa, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed May 31 16:54:00 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942836, encodeId=357c194283643, content=<a href='/topic/show?id=5244385233f' target=_blank style='color:#2F92EE;'>#可视化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38523, encryptionId=5244385233f, topicName=可视化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Wed Dec 28 19:54:00 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348018, encodeId=834f1348018f7, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Jul 05 22:54:00 CST 2016, time=2016-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375277, encodeId=1e5613e527708, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Tue Jul 05 22:54:00 CST 2016, time=2016-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420159, encodeId=9bd214201594e, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Tue Jul 05 22:54:00 CST 2016, time=2016-07-05, status=1, ipAttribution=)]
    2017-05-31 mjldent
  2. [GetPortalCommentsPageByObjectIdResponse(id=1747211, encodeId=5dfe1e47211fa, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed May 31 16:54:00 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942836, encodeId=357c194283643, content=<a href='/topic/show?id=5244385233f' target=_blank style='color:#2F92EE;'>#可视化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38523, encryptionId=5244385233f, topicName=可视化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Wed Dec 28 19:54:00 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348018, encodeId=834f1348018f7, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Jul 05 22:54:00 CST 2016, time=2016-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375277, encodeId=1e5613e527708, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Tue Jul 05 22:54:00 CST 2016, time=2016-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420159, encodeId=9bd214201594e, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Tue Jul 05 22:54:00 CST 2016, time=2016-07-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1747211, encodeId=5dfe1e47211fa, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed May 31 16:54:00 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942836, encodeId=357c194283643, content=<a href='/topic/show?id=5244385233f' target=_blank style='color:#2F92EE;'>#可视化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38523, encryptionId=5244385233f, topicName=可视化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Wed Dec 28 19:54:00 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348018, encodeId=834f1348018f7, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Jul 05 22:54:00 CST 2016, time=2016-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375277, encodeId=1e5613e527708, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Tue Jul 05 22:54:00 CST 2016, time=2016-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420159, encodeId=9bd214201594e, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Tue Jul 05 22:54:00 CST 2016, time=2016-07-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1747211, encodeId=5dfe1e47211fa, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed May 31 16:54:00 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942836, encodeId=357c194283643, content=<a href='/topic/show?id=5244385233f' target=_blank style='color:#2F92EE;'>#可视化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38523, encryptionId=5244385233f, topicName=可视化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Wed Dec 28 19:54:00 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348018, encodeId=834f1348018f7, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Jul 05 22:54:00 CST 2016, time=2016-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375277, encodeId=1e5613e527708, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Tue Jul 05 22:54:00 CST 2016, time=2016-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420159, encodeId=9bd214201594e, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Tue Jul 05 22:54:00 CST 2016, time=2016-07-05, status=1, ipAttribution=)]
    2016-07-05 jichang
  5. [GetPortalCommentsPageByObjectIdResponse(id=1747211, encodeId=5dfe1e47211fa, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed May 31 16:54:00 CST 2017, time=2017-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942836, encodeId=357c194283643, content=<a href='/topic/show?id=5244385233f' target=_blank style='color:#2F92EE;'>#可视化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38523, encryptionId=5244385233f, topicName=可视化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Wed Dec 28 19:54:00 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348018, encodeId=834f1348018f7, content=<a href='/topic/show?id=d61b418860a' target=_blank style='color:#2F92EE;'>#基因表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41886, encryptionId=d61b418860a, topicName=基因表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Jul 05 22:54:00 CST 2016, time=2016-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375277, encodeId=1e5613e527708, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Tue Jul 05 22:54:00 CST 2016, time=2016-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420159, encodeId=9bd214201594e, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Tue Jul 05 22:54:00 CST 2016, time=2016-07-05, status=1, ipAttribution=)]

相关资讯

Science:重大发现!利用MANF的免疫调节性提高视网膜移植成功率

基于细胞替换的再生疗法有望治疗一系列年龄相关性疾病,但是将这些疗法用于在临床上治疗病人的努力却并不是非常成功,这很大程度上是因为新获得的替换细胞不能够有效地整合到受到衰老影响的组织中。在一项新的研究中,来自美国巴克老龄研究所(Buck Institute for Research on Aging)的研究人员利用一种自然发生的进化上古老的修复眼睛的抗炎机制,显著性地提高小鼠体内的视网膜再生疗法的成

干细胞治疗:天使or恶魔?

未经监管的细胞免疫疗法抓住癌症患者绝望的心理,号称回输免疫细胞就能杀死患者体内的癌细胞。上当受骗的患者,往往人财两空,直接导致了‘魏则西’事件的发生。然而在细胞治疗的大浪中,另一项和免疫疗法并重的所谓“干细胞疗法”,却依然隐匿在公众的视野中。有很多人花了大价钱,接受了干细胞疗法,他们的病被治好了么?干细胞疗法会导致下一个魏则西的出现么? 干细胞被誉为‘不老泉’(fountain of

脑瘤治疗重大突破!液态阿司匹林杀死脑癌细胞的效率比化疗提高10倍!

昨天(2016年6月28日)在波兰首都华沙举行的“脑瘤 2016---从生物学到治疗(Brain Tumours 2016 – From Biology to Therapy)”国际研究会议上,一项潜在里程碑性的科学突破对未来的脑瘤治疗产生极其深远的影响。 依据这项突破性的研究,含有液态阿司匹林的饮料可能能够延长上千名脑癌患者的寿命。 研究人员发现这种简单的药物能够穿过血脑

Nat Commun:手术前利用液体活检标记物检测前列腺癌侵袭性

近日,来自加拿大多伦多大学的研究人员利用非侵入性液体活检方法发现了前列腺癌生物标记物,能够在手术前帮助鉴定侵袭性前列腺癌。   该研究发表在国际学术期刊Nature Communication上,研究人员认为对于许多男性来说生长缓慢低风险的前列腺癌可能永远都不需要进行手术治疗,而目前全世界存在许多过度治疗问题,该研究将推动精确的非侵入性诊断工具的开发。   目前临床

新型眼镜可矫正色盲

吉米与杰斯是一对苦命兄弟:他们两个人都是色盲症患者。然而,他们不幸的生活随着一副眼镜的出现发生了改变。这一天,兄弟俩的父母给他们买了一副"EnChroma"眼镜。在吉米戴上眼镜之前,父亲把手里攥着的五颜六色的气球一个个拿出来:"看,这是什么颜色?" "橙色?" "不,是绿色"。之后,吉米戴上了这幅眼镜,神奇的一幕发生了:他看到了披着亮色沙滩浴巾的爸爸手里拿着的五颜六色的气球,一个个鲜艳无比。吉米的

中国:一个超级DNA测序大国 如今将转战精准医学研究领域

6年前,中国成为DNA测序的全球领导者,而这多数归功于华大基因(BGI)公司的贡献,位于深圳的华大基因公司已经购买了128台全球最快的测序机器,而公司解析DNA的能力已经超过全球50%,BGI组成了一支非常年轻的生物信息学家团队,并且同全球的研究者进行合作,如今已经发布了从古人类到大熊猫等各个物种的测序结果,同时公司也因作为一个巨大的基因组工厂而获得了众多的声望。 6年后,公